CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Executive or director change
- 4 Grant or award SVP, General Counsel acquired 144,928 shares (grant or award)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 173,913 shares (grant or award)
- 4 Grant or award SVP, Finance acquired 36,232 shares (grant or award)
- 4 Grant or award EVP of R&D acquired 173,913 shares (grant or award)
- 4 Grant or award Director acquired 369,957 shares (grant or award)
- 4 Grant or award President and CEO acquired 552,174 shares (grant or award)
- 4 Open-market sale EVP of R&D sold 27,199 shares at $1.78 ($48,414)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 9,136 shares at $2.18 ($19,916)
- 4 Open-market sale Director sold 9,221 shares at $2.16 ($19,917)
- 144 Insider Sale of Securities
- 144/A Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Other events
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 10-Q Report Quarterly Report
Page 8 of 30 · 587 filings